Diabetic ketoacidosis and olanzapine: Case report and literature review
1 Undergraduate Student of Medicine at UnP - Potiguar University - Laureate International Universities – Natal/Brazil.
2 Endocrinologist and Professor of the Medical Undergraduate Course - Potiguar University - Laureate International Universities – Natal/Brazil.
3 Postgraduate Program in Biotechnology at Potiguar University/ UnP - Laureate International Universities – Natal/Brazil. Ph.D. in Health Science.
Research Article
GSC Biological and Pharmaceutical Sciences, 2019, 09(03), 013-019.
Article DOI: 10.30574/gscbps.2019.9.3.0216
Publication history:
Received on 18 November 2019; revised on 03 December 2019; accepted on 04 December 2019
Abstract:
The use of antipsychotics (AP) is associated with the development of metabolic disorders, such as diabetic ketoacidosis (DKA) and acute dysregulation of glucose metabolism. Hyperglycemic complications from drug use, although rare, are potentially life-threatening, so appropriate follow-up and risk assessment during treatment are necessary. This study reports the case of a patient with bipolar affective disorder using olanzapine who developed severe DKA and reviews the current literature on this association. The research was done in PubMed, Cochrane Database, Scopus, Web of Science, Embase, and Google Scholar databases using the keywords: diabetes mellitus, diabetic ketoacidosis, psychotic disorders, antipsychotics, olanzapine, adverse drug event. Upon analysis of the included epidemiological studies, it was observed that most patients who developed DKA were undergoing treatment with olanzapine and clozapine alone or in combination with other antipsychotics. It was seen that the DKA picture usually occurs between six to twelve months of AP use, similar to the case presented. Before insulin resistance, male gender, and middle age favor the disorder in AP users.
Keywords:
Diabetes mellitus; Diabetic ketoacidosis; Psychotic disorders; Antipsychotics; Olanzapine; Adverse drug event
Full text article in PDF:
Copyright information:
Copyright © 2019 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
